Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Snowe/Wyden May Eliminate Open Enrollment Feature, Tobacco Tax Funding

Executive Summary

The open enrollment provision in the Snowe/Wyden Medicare prescription drug benefit plan may be revised if the bill moves forward, Sen. Wyden (D-Wash.) health policy advisor Stephanie Kennan said at the American Pharmaceutical Association annual meeting in Washington, D.C. March 13.

You may also be interested in...



Breaux Interim Medicare Rx Plan Would Cover Low-Income And Stop-Loss

An interim Medicare drug benefit being considered by Sen. Breaux (D-La.) would include both low-income and stop-loss subsidies, Breaux indicated at a March 22 Senate Finance Committee hearing.

Breaux Interim Medicare Rx Plan Would Cover Low-Income And Stop-Loss

An interim Medicare drug benefit being considered by Sen. Breaux (D-La.) would include both low-income and stop-loss subsidies, Breaux indicated at a March 22 Senate Finance Committee hearing.

Breaux/Frist FFS Premium Increase Would Be 25% With Cap Change - HCFA

The Breaux/Frist Medicare reform plan would result in a 25% increase in fee-for-service premiums in 2003, assuming the plan's premium cap reflects the current market trend, the Health Care Financing Administration estimates.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS035770

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel